Harvard Bioscience (HBIO) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HBIO Hot Sheet
Price: $8.68 +0.12%
EPS Growth %: -800.0%
Financial Fact:
General and administrative expenses: 4.8M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: -800.0%
Financial Fact:
General and administrative expenses: 4.8M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Harvard Bioscience (NASDAQ: HBIO) reported Q3 EPS of ($0.02), $0.04 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $21.97 million versus the consensus estimate of $23.7 million.
For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LegalZoom (LZ) Misses Q3 EPS by 1c; Offers Guidance
- Allegiant Travel (ALGT) Tops Q3 EPS by 45c ; Offers Guidance
- Sinclair Broadcast Group (SBGI) Tops Q3 EPS by 31c; updates guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
